USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceutical corp - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin capsules, usp are indicated for the management of postherpetic neuralgia in adults. gabapentin capsules, usp are indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. gabapentin capsules are also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 -12 years. gabapentin capsules are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. the abuse and dependence potential of gabapentin capsules has not been evaluated in human studies.

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceutical corp - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - ergotamine tartrate 1 mg - indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”. coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine tartrate and caffeine was coadministered, at least one resulting in death. because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drug and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors). ergotamine tartrate and caffeine may cause fetal harm when administered to pregnant women. ergotamine tartrate and ca

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceutical corp - sertraline hydrochloride (unii: uti8907y6x) (sertraline - unii:quc7nx6wmb) - sertraline hydrochloride 25 mg - sertraline is indicated for the treatment of major depressive disorder in adults. the efficacy of sertraline hydrochloride in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical trials under clinical pharmacology). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the antidepressant action of sertraline hydrochloride in hospitalized depressed patients has not been

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - acetaminophen 325 mg

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - codeine sulfate (unii: 11qv9bs0cb) (codeine anhydrous - unii:ux6owy2v7j) - codeine sulfate 15 mg

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 50 mg - losartan potassium and hydrochlorothiazide is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a var

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 4 mg - galantamine is indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine is contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. pregnancy category c there are no adequate and well-controlled studies in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically. galantamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in rats, administration of galantamine (oral doses of 2 mg, 8 mg, or 16 mg/kg/day), from day 14 (females) or day 60 (males) prior to mating and continuing in females through the period of organogenesis, resulted in an increased incidence of fetal skeletal variations at the two highest doses. the no-effect dose fo

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - valacyclovir hydrochloride (unii: g447s0t1vc) (acyclovir - unii:x4hes1o11f) - valacyclovir 500 mg

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin is indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9) ]. clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9) ]. clarithromycin is indicated [see indications and usage (1.9) ] for the treatment of mild to moderate infections caused by susceptible isolates due to: clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates due to staphylococcus aureus, or streptococcus pyogenes . clari

USA - engelsk - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg - dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: dutasteride in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. dutasteride is not approved for the prevention of prostate cancer. dutasteride is contraindicated for use in: pregnancy category x. dutasteride is contraindicated for use in women of childbearing potential and during pregnancy. dutasteride is a 5 alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. in animal reproduction and developmental toxicity studies, dutasteride inhibited normal development of external genitalia in male fetuses. therefore, dutasteride may cause fetal harm when administered to a pregnant woman. if dutasteride is used during pregnancy or if the patient becomes pregnant while taking dutasteride, the